Article Sidebar

pdf
Date Published: 17/10/2024
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v543i2.11388
Issue
Vol. 543 No. 2 (2024)
Section
Các bài báo
How to Cite
Nguyễn, T. H., Nguyễn, T. T. H., Nguyễn, T. T. H., & Vũ, H. T. (2024). TREATMENT RESULTS OF METASTATIC NASOPHARYNGEAL CANCER BY GEMCITABINE-CISPLATIN AT NGHE AN ONCOLOGY HOSPITAL. Vietnam Medical Journal, 543(2). https://doi.org/10.51298/vmj.v543i2.11388

TREATMENT RESULTS OF METASTATIC NASOPHARYNGEAL CANCER BY GEMCITABINE-CISPLATIN AT NGHE AN ONCOLOGY HOSPITAL

Thị Hiếu Nguyễn, Thị Thái Hòa Nguyễn, Thị Thái Hòa Nguyễn, Hồng Thăng Vũ

Main Article Content

Abstract

Aims: To evaluate the result of Gemcitabine - Cisplatin in patients with metastatic nasopharyngeal cancer in Nghe An Oncology Hospital. Method: Retrospective study on 39 metastatic nasopharyngeal cancer patients who received first-line treatment with Gemcitabine - Cisplatin regimen in Nghe An Oncology Hospital from January 2019 to April 2024. Results: The most common site of metastasis was lung (43,6%), followed by the liver (38,5%); bone (33,3%). The overal response rate (ORR) was 71,7% and  the  median  PFS  was  9,0  months; The most common was neutropenia (74,3%), anemia (64%), nausea (56,4%), vomiting (43,6%) most of them were grade 1, 2. Conclusion: Gemcitabine-Cisplatin was an effective and tolerable regimen in patients with metastatic nasopharyngeal cancer.

Article Details

Keywords

nasopharyngeal cancer, Gemcitabine – Cisplatin

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. doi:10.3322/caac.21834
2. Bộ Y tế. Hướng Dẫn Chẩn Đoán và Điều Trị Một Số Bệnh Ung Bướu.; 2020:164-173.
3. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012; 138 (10): 1717-1725. doi:10.1007/s00432-012-1219-x
4. Ngan RKC, Yiu HHY, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13(8):1252-1258. doi:10.1093/annonc/mdf200
5. Hsieh JCH, Hsu CL, Ng SH, et al. Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Jpn J Clin Oncol. 2015;45(9): 819-827. doi:10.1093/jjco/ hyv083
6. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet Lond Engl. 2016; 388(10054): 1883-1892. doi:10.1016/S0140-6736(16)31388-5
7. Nguyễn TPA, Đỗ HK. KẾT QUẢ ĐIỀU TRỊ UNG THƯ VÒM MŨI HỌNG GIAI ĐOẠN MUỘN BẰNG PHÁC ĐỒ GEMCITABINE – CISPLATIN TẠI BỆNH VIỆN K. Tạp Chí Học Việt Nam. 2021;507(2). doi:10.51298/vmj.v507i2.1435